IP Library Granted Patent US 9,968,679
Granted Patent B2
US 9,968,679 · App. 14/763,304 · Granted May 15, 2018

Clear aqueous solution

Inventors: Yuko Shikamura (Hyogo, JP); Yuka Higashimura (Hyogo, JP)
Assignee: SENJU PHARMACEUTICAL CO., LTD.
A61K47/186A61K9/0048A61K9/08A61K31/427A61K47/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,968,679
App. No.
14/763,304
Granted
May 15, 2018
Kind
B2
Abstract

The present invention provides a stable and clear aqueous liquid preparation containing (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof as an active ingredient, and benzalkonium chloride represented by the formula: [C 6 H 5 CH 2 N(CH 3 ) 2 R]Cl wherein R is an alkyl group having 8-18 carbon atoms.

Claims (61)

1. An aqueous liquid preparation comprising: (1) (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof, and (2) at least one benzalkonium chloride,

wherein benzalkonium chloride is represented by the formula:

[C 6 H 5 CH 2 N(CH 3 ) 2 ]Cl

wherein R is an alkyl group having 8-18 carbon atoms,

wherein the transmittance of the aqueous liquid preparation at wavelength 600 nm is not less than 98%,

wherein the (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or the pharmaceutically acceptable salt thereof has a concentration selected from the range of the lower limit concentration of about 0.0002 w/v % and the upper limit concentration of about 0.05 w/v % relative to the total amount of the aqueous liquid preparation,

wherein the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 8 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % when R is an alkyl group having 10 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.003 w/v % or higher than 0.01 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 12 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 14 carbon atoms,

wherein the benzalkonium chloride has a concentration other than 0.001 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 16 carbon atoms, and

wherein a mixture of the benzalkonium chlorides has a total concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when the mixture comprises (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms and (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms.

2. The aqueous liquid preparation according to claim 1 , wherein R is an alkyl group having 8 carbon atoms, and the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation.

3. The aqueous liquid preparation according to claim 1 , wherein R is an alkyl group having 10 carbon atoms, and the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation.

4. The aqueous liquid preparation according to claim 1 , wherein R is an alkyl group having 12 carbon atoms, and the benzalkonium chloride has a concentration of less than 0.003 w/v % or higher than 0.01 w/v % relative to the total amount of the aqueous liquid preparation.

5. The aqueous liquid preparation according to claim 1 , wherein R is an alkyl group having 14 carbon atoms, and the benzalkonium chloride has a concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation.

6. The aqueous liquid preparation according to claim 1 , wherein R is an alkyl group having 16 carbon atoms, and the benzalkonium chloride has a concentration other than 0.001 w/v % relative to the total amount of the aqueous liquid preparation.

7. The aqueous liquid preparation according to claim 1 , wherein R is an alkyl group having 18 carbon atoms.

8. The aqueous liquid preparation according to claim 1 , comprising a mixture of (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms and (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms, and the total concentration of the benzalkonium chloride mixture relative to the total amount of the aqueous liquid preparation is less than 0.001 w/v % or higher than 0.002 w/v %.

9. The aqueous liquid preparation according to claim 1 , further comprising a surfactant.

10. The aqueous liquid preparation according to claim 9 , wherein the surfactant is tyloxapol.

11. An ophthalmic solution comprising: (1) (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof, and (2) at least one benzalkonium chloride,

wherein benzalkonium chloride is represented by the formula:

[C 6 H 5 CH 2 N(CH 3 ) 2 R]Cl

wherein R is an alkyl group having 8-18 carbon atoms,

wherein the transmittance of the aqueous liquid preparation at wavelength 600 nm is not less than 98%,

wherein the (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or the pharmaceutically acceptable salt thereof has a concentration selected from the range of the lower limit concentration of about 0.0002 w/v % and the upper limit concentration of about 0.05 w/v % relative to the total amount of the aqueous liquid preparation,

wherein the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 8 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % when R is an alkyl group having 10 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.003 w/v % or higher than 0.01 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 12 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 14 carbon atoms, and

wherein the benzalkonium chloride has a concentration other than 0.001 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 16 carbon atoms, and

wherein a mixture of the benzalkonium chlorides has a total concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when the mixture comprises (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms and (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms.

12. A method of preparing the aqueous liquid preparation of claim 1 comprising:

adding at least one benzalkonium chloride, wherein benzalkonium chloride is represented by the formula:

[C 6 H 5 CH 2 N(CH 3 ) 2 R]Cl

wherein R is an alkyl group having 8-18 carbon atoms to an aqueous liquid solution comprising (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or a pharmaceutically acceptable salt thereof,

wherein the (3-{2-[4-isopropyl-2-(4-trifluoromethyl)phenyl-5-thiazolyl]ethyl}-5-methyl-1,2-benzisoxazol-6-yl)oxyacetic acid or the pharmaceutically acceptable salt thereof has a concentration selected from the range of the lower limit concentration of about 0.0002 w/v % and the upper limit concentration of about 0.05 w/v % relative to the total amount of the aqueous liquid preparation,

wherein the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 8 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % when R is an alkyl group having 10 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.003 w/v % or higher than 0.01 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 12 carbon atoms,

wherein the benzalkonium chloride has a concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 14 carbon atoms,

wherein the benzalkonium chloride has a concentration other than 0.001 w/v % relative to the total amount of the aqueous liquid preparation when R is an alkyl group having 16 carbon atoms, and

wherein a mixture of the benzalkonium chlorides has a total concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation when the mixture comprises (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms and (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms, and

wherein the transmittance of the aqueous liquid preparation at wavelength 600 nm is not less than 98%.

13. The method according to claim 12 , wherein R is an alkyl group having 8 carbon atoms, and wherein the benzalkonium chloride is added at a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation.

14. The method according to claim 12 , wherein R is an alkyl group having 10 carbon atoms, and wherein the benzalkonium chloride is added at a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation.

15. The method according to claim 12 , wherein R is an alkyl group having 12 carbon atoms, and wherein the benzalkonium chloride is added at a concentration of less than 0.003 w/v % or higher than 0.01 w/v % relative to the total amount of the aqueous liquid preparation.

16. The method according to claim 12 , wherein R is an alkyl group having 14 carbon atoms, and wherein the benzalkonium chloride is added at a concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation.

17. The method according to claim 12 , wherein R is an alkyl group having 16 carbon atoms, and wherein the benzalkonium chloride is added at a concentration other than 0.001 w/v % relative to the total amount of the aqueous liquid preparation.

18. The method according to claim 12 , wherein R is an alkyl group having 18 carbon atoms.

19. The method according to claim 12 , comprising adding a mixture of benzalkonium chlorides, wherein the mixture comprises (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms and (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms, and the total concentration of the benzalkonium chloride mixture is less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation.

20. The ophthalmic solution according to claim 11 , wherein R is an alkyl group having 8 carbon atoms, and the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation.

21. The ophthalmic solution according to claim 11 , wherein R is an alkyl group having 10 carbon atoms, and the benzalkonium chloride has a concentration of less than 0.05 w/v % or higher than 0.1 w/v % relative to the total amount of the aqueous liquid preparation.

22. The ophthalmic solution according to claim 11 , wherein R is an alkyl group having 12 carbon atoms, and the benzalkonium chloride has a concentration of less than 0.003 w/v % or higher than 0.01 w/v % relative to the total amount of the aqueous liquid preparation.

23. The ophthalmic solution according to claim 11 , wherein R is an alkyl group having 14 carbon atoms, and the benzalkonium chloride has a concentration of less than 0.001 w/v % or higher than 0.002 w/v % relative to the total amount of the aqueous liquid preparation.

24. The ophthalmic solution according to claim 11 , wherein R is an alkyl group having 16 carbon atoms, and the benzalkonium chloride has a concentration other than 0.001 w/v % relative to the total amount of the aqueous liquid preparation.

25. The ophthalmic solution according to claim 11 , wherein R is an alkyl group having 18 carbon atoms.

26. The ophthalmic solution according to claim 11 , comprising a mixture of (i) a first benzalkonium chloride wherein R is an alkyl group having 12 carbon atoms and (ii) a second benzalkonium chloride wherein R is an alkyl group having 14 carbon atoms, and the total concentration of the benzalkonium chloride mixture relative to the total amount of the aqueous liquid preparation is less than 0.001 w/v % or higher than 0.002 w/v %.

27. The ophthalmic solution according to claim 11 , further comprising a surfactant.

28. The ophthalmic solution according to claim 27 , wherein the surfactant is tyloxapol.

Assignments (2)
CHANGE OF ADDRESS Recorded Aug 24, 2018
From: SENJU PHARMACEUTICAL CO., LTD.
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 046835/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2015
From: SHIKAMURA, YUKO; HIGASHIMURA, YUKA
To: SENJU PHARMACEUTICAL CO., LTD.
Reel/Frame 036173/0946 →
Priority Claims (2)
JP 2013-017876 · Jan 31, 2013 · national
JP 2013-267724 · Dec 25, 2013 · national
Continuity (1)
Related Publication 20150366969A1 · Dec 24, 2015